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Abstract
Loss-of-function variants in innate immunity genes are associated with Mendelian disorders in the form of primary
immunodeficiencies. Recent resequencing projects report that stop-gains and frameshifts are collectively prevalent in
humans and could be responsible for some of the inter-individual variability in innate immune response. Current
computational approaches evaluating loss-of-function in genes carrying these variants rely on gene-level characteristics
such as evolutionary conservation and functional redundancy across the genome. However, innate immunity genes
represent a particular case because they are more likely to be under positive selection and duplicated. To create a ranking of
severity that would be applicable to innate immunity genes we evaluated 17,764 stop-gain and 13,915 frameshift variants
from the NHLBI Exome Sequencing Project and 1,000 Genomes Project. Sequence-based features such as loss of functional
domains, isoform-specific truncation and nonsense-mediated decay were found to correlate with variant allele frequency
and validated with gene expression data. We integrated these features in a Bayesian classification scheme and
benchmarked its use in predicting pathogenic variants against Online Mendelian Inheritance in Man (OMIM) disease stop-
gains and frameshifts. The classification scheme was applied in the assessment of 335 stop-gains and 236 frameshifts
affecting 227 interferon-stimulated genes. The sequence-based score ranks variants in innate immunity genes according to
their potential to cause disease, and complements existing gene-based pathogenicity scores. Specifically, the sequence-
based score improves measurement of functional gene impairment, discriminates across different variants in a given gene
and appears particularly useful for analysis of less conserved genes.
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Introduction
There is considerable variability in the human immune response
to pathogens. The observation of genetic causes of a number of
primary immunodeficiencies underscores the fundamental role of
variants in immune genes - in many cases resulting in severe,
pathogen-specific disorders [1]. A main challenge in the analysis of
genome variation today is the assignment of a functional role to
rare variants [2]. Here, large numbers of study participants would
not necessarily provide the statistical power to associate a genotype
with a phenotype. In this context, efforts are put toward to the
computational identification of features allowing prioritization of
variants for follow-up in genetic and functional analysis. Strategies
to attribute a severity score to a variant, recently reviewed in [3],
include approaches based on evolutionary, physico-chemical and
structural properties (Polyphen2 [4], SIFT [5]), methods based on
analysis of mutation load (e.g. the Residual Variation Intolerance
Score, RVIS [6]), and integrative pipelines [7–10].
Of special interest in the study of inter-individual variability in
innate immunity is the evaluation of stop-gains and frameshifts.
Such variants are prevalent, having an estimated number of 100 to
200 occurrences per human genome [11,12]. Stop-gains and
frameshifts may lead to functional consequences due to protein
truncation, degradation of the transcript by Nonsense-Mediated
Decay (NMD) [13] and dominant negative influences of protein
species. In particular, rare and young variants that have not
undergone purifying selection may contribute to burden of disease
in a population [14–16]. Despite a stop-gain or frameshift variant,
however, the function of a protein may be preserved because of
limited truncation of functional and structural domains, or because
the variant affects only one of the splice forms. A less understood
possibility is the occurrence of stop-codon read-through [17,18].
Analyses based on gene characteristics such as evolutionary
conservation and non-redundancy in the genome [19], or
mutational burden analysis [6] are used to predict the severity of
stop-gain and frameshift variants. Herein, we refer to these
analyses as ‘‘gene-based’’. However, innate immunity genes tend
to be less conserved and more duplicated than the genome average
[20] and other features may be needed to assess functional
relevance of a variant. The aim of this study is to explore sequence
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characteristics that may improve the understanding of the
functional consequences of stop-gain and frameshift variants in
innate immunity genes. Herein, we will refer to these analyses as
‘‘sequence-based’’. For this, we first evaluated two sets of publicly
available data from a total of 7595 individuals [16,21] including
gene expression data from 421 of them [22]. Specific sequence
features of truncating variants were found to correlate with allele
frequency and gene expression levels. These features were used to
generate a pathogenicity score that was evaluated through
benchmark against OMIM disease variants. The approach was
applied to assess functional consequences of stop-gain and
frameshift variants in innate immunity genes, with particular
attention to antiviral interferon-stimulated genes (ISGs).
Results
Variant set
We analysed gene variant data from a total of 7595 individuals
from the NHLBI GO Exome Sequencing Project (ESP) [16] and
the 1000 Genomes Project [21]. We considered 17764 stop-gain
and 13915 frameshift variants collectively affecting 11369 autoso-
mal protein coding genes reliably annotated by the Consensus
CDS (CCDS) project [23]. The distributions of gene truncating
variants according to allele frequency and study are presented in
Table S1.
Distribution of variants in sequence-based features
Consistent with previous reports [19,24], we observed that the
distribution of stop-gain and frameshift variants along the protein
coding sequence of genes is biased by allele frequency (Figure
S1). Variants with very low allele frequency (MAF#0.001)
are evenly distributed, with a modest 39 terminal enrichment.
However, the distribution of stop-gain and frameshift variants
becomes less uniform with increasing allele frequencies, yet does
not show a clear pattern. In contrast, we observed marked
distribution trends in association with the following sequence
features: (i) loss of functional domains; (ii) disruption of constitutive
exons (i.e. exons present in all isoforms), or of principal isoforms;
(iii) localization in potential NMD-targeted regions. In comparison
to rare truncating variants, common stop-gain and frameshift
variants were clearly depleted at positions leading to the loss of a
functional domain (Figure 1A). Analysis of splicing-dependent
effects was limited to genes with multiple annotated transcripts in
CCDS (n = 5203). We observed an enrichment of common stop-
gain and frameshift variants in alternative isoforms (Figure 1B)
and a depletion of common variants in principal isoforms
(Figure 1C). Defining principal isoform on the basis of highest
expression level across tissues [25] showed comparable results. We
observed that common gene truncating variants occurred less
frequently in regions more than fifty nucleotides upstream the last
exon-exon junction, possibly triggering NMD-mediated transcript
degradation (Figure 1D). For all the features discussed above,
gene-truncating variants associated with disease in the Online
Mendelian Inheritance in Man (OMIM) database exhibited a
distribution bias opposite to what was observed for common stop-
gain and frameshift variants (Figure 1). The same trends were
observed when ESP and 1000 Genomes variant datasets were
analysed separately (Figure S2).
Expression analysis
We used expression data from 421 individuals to assess the
functional impact of stop-gain and frameshift variants [22]. In
particular, we evaluated differences between protein truncating
variants localized to NMD-targeted region compared to those that
were not. Stop-gains predicted to trigger NMD (n = 756) had a
significantly lower expression level (median Z-score =20.59) than
stop-gains predicted to escape NMD (n = 379, median =20.10)
and lower than a reference distribution of synonymous variants
(median =20.04, one-sided Wilcoxon rank-sum test p-value,
2.2e-16) (Figure 2A). Among stop-gains predicted to trigger
NMD, singletons (n = 488, median Z-score =20.75) showed a
stronger decrease in expression level compared to non-singletons
(n = 268, median =20.26, p-value = 1.3e-10, Figure 2B), which
is an indication that they represent actual variants and not
sequencing or bioinformatics errors. We did not observe a similar
reduction when considering 87 of the 172 frameshift variants with
expression data mapping to potential NMD-target regions
(median =20.14, p-value = 5.7e-02).
To further evaluate a splicing-dependent impact on gene
expression levels, we limited the analysis to 301 stop-gains
predicted to trigger NMD and affecting genes with multiple
isoforms described in CCDS. We observed a significant decrease
in gene expression levels of NMD-triggering stop-gains affecting all
isoforms (n = 216, median =20.64) compared to those affecting
only a fraction of isoforms (n = 85, median =20.22, one-sided
Wilcoxon rank-sum test p-value = 2.5e-03) (Figure 2C). Similar
results were obtained using RPKM normalized expression values
(Figure S3). These observations confirmed the functional impact
of stop-gains consistently with predictions of degradation by NMD
and current annotation of isoforms.
Pathogenicity scores
We then evaluated the predictive value for pathogenicity of the
sequence-based features characterized in the previous sections:
percentage of sequence affected, loss of functional domains,
proportion of isoforms affected, principal isoform damage, and
NMD-target region. We integrated them into a naı¨ve Bayes
classifier (Table S3) and assessed its performance over a dataset of
1160 pathogenic stop-gain variants found in the OMIM database
and 125 common stop-gain variants that are not known to be
pathogenic. Predictive performance of the pathogenicity score was
validated over unseen variants excluded from the learning data
using successive random subsampling (see Methods). The classifier
was benchmarked against a state of the art gene-based probability
score proposed by MacArthur et al [19]. This gene-based score
Author Summary
There are well-characterized severe immunodeficiencies
associated with loss-of-function variants in innate immu-
nity genes. Genome sequencing projects identify rare
stop-gain and frameshift variants in innate immunity
genes whose phenotype is uncharacterized. Current
methods to estimate the severity of rare stop-gains and
frameshifts are based on evolutionary conservation of the
gene, the likelihood for redundancy in its function or
mutational burden. These parameters are not always
applicable to innate immunity genes. We evaluated
sequence-level characteristics of more than 30’000 stop-
gains and frameshifts and prioritized variants according to
their predicted functional consequences. Our scoring
approach complements existing tools in the prediction
of innate immunity OMIM disease variants and associates
with functional readouts such as gene expression. In this
framework, we show that many individuals do carry highly
pathogenic variants in genes participating in antiviral
defense. The clinical assessment of these variants is of
significant interest.
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relies on conservation and protein interaction network proximity
to genes associated to a recessive disease as predictive features. In
the case of stop-gain variants, the performance of the gene-based
method was consistent with the reported results in the original
work (Area Under the Curve (AUC) = 0.83, Figure 3A). Similar
ROC curves were obtained with the gene-based score RVIS [6]
that provides a measure of the departure from the average number
of common functional mutations in genes with a similar amount of
mutational burden (Figure S4). The score based on sequence
features alone showed a lower predictive value (AUC = 0.67).
However, optimal ROCs were achieved by combining sequence
and gene-based scores (Figure 3). We observe that at a False
Positive Rate (FPR) of less than 0.1 there is no improvement from
the combined sequence-based and from the MacArthur gene-
based score that used network proximity OMIM recessive disease
genes in its design. Improvement at low FPR occurs in the
combination of the sequence-based score with RVIS, which does
not rely on OMIM annotations. While the AUC improvement is
modest, it is consistent across two datasets (ESP and 1000
Genomes), over the two gene-based scores, and for the two types of
variants (stop-gains and frameshifts), Figure S4. These results
demonstrate that sequence features can be incorporated as an
Figure 1. Distribution of variants according to sequence features and allele frequency. The y-axis represents the percentage of variants
for the allele frequencies and categories represented in the x-axis. Panel A, percentage of variants upstream of a functional domain. Panel B, in
alternatively spliced sites. Panel C, in the principal isoform. Panel D, in regions targeted by NMD. The distribution is shown for synonymous (green),
missense (blue), stop-gain (red) and frameshift (orange) variants according to minor allele frequency (MAF) intervals, where singletons (variants
detected only in one individual) are represented separately. The pattern of OMIM disease variants and homozygous variants for each feature is
shown. The corresponding coding genome background (measured as the percentage of nucleotides displaying the feature) is shown as a grey line
(partly hidden by the distribution of synonymous variants in some panels). Numbers of variants in each category are reported in Table S2. Logistic
regression was used to model the relationship between observing a given sequence feature in a given type of variant as a function of the logarithm
of the minor allele frequency (MAF). The odds ratio estimates for stop-gain variants were significantly different from those of synonymous variants in
all panels (p-values,5e-05, heterogeneity test [40]; for frameshifts, in panels B, C and D (p-values,5e-03).
doi:10.1371/journal.pcbi.1003757.g001
Figure 2. Association of NMD-target variants with gene expression. Panel A shows the distribution of average expression z-scores for genes
from individuals carrying different types of variants (synonymous, missense, frameshift and stop-gain). Peer-factor normalized RPKM from [22] were
used. The black sector represents the distribution of variants outside the NMD-target region and the colored sector those within the NMD-target
region. Statistically significant differences were observed for stop-gain variants predicted to trigger NMD (n = 756) compared to synonymous variants
(one-sided Wilcoxon rank-sum test p-value,2.2e-16). Panel B shows the distribution of average expression z-scores described in panel A for
synonymous (grey) and stop-gain (dark and light purple) variants within the NMD-target region. The distribution of NMD-target stop-gains is
represented separately for singletons (dark purple, n = 488) and non-singletons (light purple, n = 268). Distributions are statistically different (one-
sided Wilcoxon rank-sum test = 1.3e-10). Panel C shows the distribution of average expression z-scores described in panel A for synonymous (grey)
and stop-gain (dark and light pink) variants within the NMD-target region of genes with multiple isoforms described in CCDS. The distribution of
NMD-target stop-gain is represented separately for those affecting all isoforms (dark pink, n = 216) and those affecting only a fraction of isoforms
(light pink, n = 85). Distributions are statistically different (one-sided Wilcoxon rank-sum test = 2.5e-03). Results were reproduced using RPKM
normalized expression values (Figure S3).
doi:10.1371/journal.pcbi.1003757.g002
Stop-Gains and Frameshifts in Human Innate Immunity Genes
PLOS Computational Biology | www.ploscompbiol.org 3 July 2014 | Volume 10 | Issue 7 | e1003757
additional source of information to improve current pathogenicity
prediction.
Correlation and complementarity of sequence-based and
gene-based scores
The marginal improvement obtained when scores were
combined motivated us to explore whether the different
approaches were capturing independent information. We ob-
served a very low correlation between gene-based and sequence-
based scores (Spearman rank correlation ,0.13, p-value: ,2.2e-
16 ([0.10,0.13] 95% CI from 10,000 bootstrap samples). The
reason for this observation is that the various scores are based on
different criteria: gene conservation and centrality (MacArthur
2012), burden of variation (RVIS) and sequence features (current
work). Correlations were not increased in analyses limited to
OMIM disease variants (Figure S5). Based on these results we
explored the potential for complementarity across scores.
First, we analysed whether the sequence-based score was better
powered to detect functional impact as measured by effect on gene
expression. We observed a stronger correlation with expression
levels for the sequence-based score (Spearman rank correla-
tion = 0.2160.03, p-value: ,5e-12) than either gene-based scores
(0.0660.04, p-value.0.05 for MacArthur 2012 score and
0.1360.03, p-value,5e-05, for RVIS score), Figure 4. Second,
we analysed OMIM genes that carry variants annotated as
pathogenic in OMIM as well as unknown or non-pathogenic
variants. Here, the variants are scored differently using a
sequence-based approach, while all share the same gene-based
score. Figure 5 depicts this situation for 95 OMIM disease genes
carrying multiple stop-gains. The genes with the highest patho-
genicity gene-based scores also carried variants with very low
severity as determined by a sequence-based score. Third, we
checked whether the performance of the sequence-based score
varies depending on the degree of gene conservation, as measured
by dN/dS ratio in the same set of OMIM disease genes. Figure 6
shows that, for genes below the protein-coding genome average
dN/dS (0.261), the MacArthur and RVIS gene-based scores
resulted in higher pathogenicity estimates than the sequence-based
score; however without discriminating between pathogenic and
non-pathogenic/non-annotated variants. In contrast, for genes
with dN/dS$0.261, the sequence-based score performed similarly
for pathogenic variants while attributing less pathogenicity to non-
pathogenic/non-annotated variants of the same gene (Wilcoxon
signed rank test p-value,0.012). We note that OMIM variants
used here were not considered for learning in the Bayesian
classification (see Methods).
From these results, we conclude that the two types of scores are
complementary. Specifically, the sequence-based score improves
measurement of functional gene impairment, discriminates across
different variants in a given gene and appears particularly useful
for analysis of less conserved genes.
Analysis of innate immunity genes
To test the ability to rank the functional consequences of gene
truncating variants in innate immunity genes, we analysed the
distribution of both the sequenced-based and gene-based patho-
genicity scores in 1503 genes involved in innate immunity [20],
including 387 interferon stimulated genes (ISGs, [26] [27]). We
identified 856 innate immunity genes, including 230 ISGs,
carrying rare gene truncating variants (MAF,1%). Globally,
innate immunity and OMIM genes ranked higher than the
background set of the genome for both scores (Figure 7 and
Figure S6). However, the highest scores were obtained for stop-
gain variants in OMIM genes, particularly for variants in innate
immunity genes that are not observed in the ESP or the 1000
Genomes Project samples (Figure 7). The latter result is
consistent with their extreme rarity and severity. We note that
OMIM variants used here for validation were not considered for
learning in the Bayesian classification (see Methods). Despite their
apparent agreement in Figure 7, correlation between the
sequenced-based and gene-based pathogenicity scores was very
low (Spearman correlation below 0.31 in all sets of genes analyzed)
indicating that both scores provide complementary information.
Given the observation that truncating variants can be associated
with important differences in functional impact, we estimated the
number of individuals in the study population that carried variants
Figure 3. Receiver operating characteristic of the performance of pathogenicity scores for stop-gain variants. Panel A: Classification
power of three pathogenicity scores was evaluated on a set of 1160 pathogenic stop-gain variants in the OMIM database, and 125 common stop-gain
variants not known to be pathogenic. Shown are the ROC curves for the sequence-based classifier (SB) developed in this work, for the gene-based
score reported in [19] (GB), and for the joint classifier (SB6GB). Dashed curves correspond to a randomization test in which rows in sequence features
are shuffled column-wise (denoted by SB(r)). Panel B: AUC improvement achieved when combining the sequence-based scores with a gene-based
score. The panels shows AUC values of ROC curves using two independent gene-based scores (MacArthur 2012 [19] and RVIS [6]), on two
independent datasets of variants (ESP and 1000 Genomes) and two types of variants: stop-gains and frameshifts. Corresponding ROC curves and
number of pathogenic and common variants used for benchmark is shown in Figure S4. Inclusion of sequence features led to an increased area
under the ROC curve in all evaluated settings.
doi:10.1371/journal.pcbi.1003757.g003
Stop-Gains and Frameshifts in Human Innate Immunity Genes
PLOS Computational Biology | www.ploscompbiol.org 4 July 2014 | Volume 10 | Issue 7 | e1003757
consistently annotated as highly pathogenic by one or several
scores. Among 7595 individuals and 1503 innate immunity genes,
33 individuals carried rare (MAF,0.01) stop-gains and 85 carried
rare frameshifts that scored with high severity (pathogenicity rank
percentile ,= 20%) in all scores (sequence-based, MacArthur
2012 and RVIS). For the smaller set of 387 ISGs, we identified 8
individuals carrying rare stop-gains and 4 carrying rare frameshifts
with high severity in all scores.
We then focused on truncating variants in genes associated
with viral inhibition in cellular assays [26,27]. A total of 13 out of
42 genes carried such variants (observed in at least 2 people),
which were very rare overall (MAF,0.0053; Table S4).
Specifically, two genes had variants with high predicted
pathogenicity based on both scores: MX1 which controls
Influenza A virus in vitro and HPSE which is involved in
metapneumovirus, respiratory syncytial virus and yellow fever
virus control. While the gene-based scores were by definition
identical for all variants affecting a same gene, the sequenced-
based score sharply distinguished the variants according to
different predictive pathogenicity (Table S3). This observation
was consistent with the observed differences in gene expression
levels available for some of the variants.
Discussion
Numerous Mendelian disorders leading to severe infection are
caused by rare functional variation of innate immunity genes [1].
Here, we identified multiple stop-gain and frameshift variants in
this family of genes in the general population, especially among
interferon stimulated genes. These are generally heterozygous rare
variants that may or may not result in clinical consequences. To
understand the nature and possible consequences of these variants,
we first analyzed their characteristics at the genome level. The
genome-wide analysis of more than 30’000 variants provided the
statistical power to identify sequence specific features for severity
and to build a pathogenicity score. This sequence-based
pathogenicity score was then applied to the analysis of variants
in interferon stimulated genes with antiviral activity.
We observed that the distribution of stop-gain and frameshift
variants in the sequence is biased by the allele frequency. Thus, we
speculated that tolerance to these variants would reflect their
impact on functional domains, on isoforms, and on degradation by
NMD. Our results clearly underscore that rare stop-gain and
frameshift variants are subject to purifying selection [15,28].
Indeed, those variants are kept at very low frequency when they
result in the loss of functional domains, when they are located in
NMD-targeted regions, or when they disrupt the principal isoform
or constitutively spliced exons. The potential molecular impact of
heterozygous rare truncating variants was examined using mRNA
expression data [22]. Stop-gain variants predicted to trigger NMD
degradation resulted in a measurable decrease in global expression
levels. This is in line with recent findings showing a reduction in
expression levels of the variant allele compared to the reference
allele in heterozygous individuals when stop-gains occur in NMD
target regions [19,22,29]. In all analyses, singleton variants
associated with highest functional impact, consistent with higher
severity of lower frequency rare variants and indicative of
general accuracy in variant calling. A possible limitation to our
analysis is that we use lymphoblastoid cell line expression data
[22]; the impact of specific variants may be allele and tissue-
specific [30].
To further explore the functional consequences of gene
truncating variants, we analysed the collective contribution of
various severity features to the prediction of pathogenicity. For this
we built a model on a learning set that was validated through
benchmark against OMIM disease variants. These sequence-based
features improved the ranking of OMIM variants when added to a
predictive model that use gene-based features. Specifically, the
sequence-based score appeared particularly suited for functional
prediction (gene expression) and for the analysis of variants in less
conserved genes. We provide a web-based tool (http://nutvar.
labtelenti.org/) allowing the analysis of user-provided variants.
Figure 4. Correlation between pathogenicity scores of truncating variants and impact in gene-expression levels. Shown are the
distributions (y-axis) of three pathogenicity scores (Panel A: the sequence-based score developed in this work, Panel B: the gene-based score from
MacArthur 2012 [19]; Panel C: the gene-based score RVIS [6]) within quintile bins (x-axis) of the average expression z-scores from individuals carrying
stop-gain variants (Peer-factor normalized RPKM from [22] were used; see Methods and Figure 2). A total of 1060 stop-gain variants are represented,
212 in each quintile. Quintiles from 1 to 5 are ordered in decreasing impact on gene expression levels and correspond to the following intervals
respectively: z-score,21.25, (21.25, 20.66], (20.66, 20.23], (20.23, 0.23], (0.23, 5.15]. To allow comparison across scores, they are represented as
rank percentiles, where the value of a given variant accounts for the percentage of all stop-variants that had a score more pathogenic than the
variant. Therefore, a rank percentile of ‘‘0’’ indicates a variant with the highest predicted probability of being pathogenic while a rank percentile of
‘‘100’’ indicates a variant with the lowest predicted severity. A stronger correlation with expression levels was observed for the sequence-based score
(Spearman rank correlation= 0.2160.03, p-value: ,5e-12) than either gene-based scores (0.0660.04, p-value.0.05 for MacArthur 2012 score and
0.1360.03, p-value,5e-05, for RVIS score). None of the scores associated frameshift variants with gene expression levels.
doi:10.1371/journal.pcbi.1003757.g004
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We hypothesized that such a sequence-based approach would
be of particular interest for the study of innate immunity genes
because, as a group, these genes tend to be less conserved than the
genome average and hence need special consideration. The
analysis showed that our sequence-based score is able to rank
variants in innate immunity genes according to their pathogenicity
and provides complementary information to previously proposed
gene-based scores. Indeed we found that in the case of the antiviral
genes MX1 and HPSE, truncating variants ranked very highly in
pathogenicity on the basis of gene-based scores while important
differences were observed at sequence level suggesting significant
differences in functional impact. For example the MX1 stop-gain
Figure 5. Complementarity between sequence-based and gene-based pathogenicity scores illustrated for OMIM genes with both
pathogenic and non-pathogenic/non-annotated stop-gain variants. Shown are the sequence-based score (x-axis) for 273 stop-gain variants
reported by the ESP and 1000 Genomes datasets in 75 OMIM genes carrying both OMIM pathogenic-variants (grey dots) and a non-pathogenic/non-
annotated variants (orange dots). Genes are displayed by blocks from 1 to 9 (y-axis on the right) corresponding to deciles of the gene-based
MacArthur 2012 rank percentile (e.g. 1: ,= 10; 2: (10,20], etc). Grey triangles beside the panels represent the direction of increasing pathogenicity for
the corresponding scores.
doi:10.1371/journal.pcbi.1003757.g005
Stop-Gains and Frameshifts in Human Innate Immunity Genes
PLOS Computational Biology | www.ploscompbiol.org 6 July 2014 | Volume 10 | Issue 7 | e1003757
rs35132725 exhibits all the features of severity and a negative
effect on expression levels. In contrast, the MX1 frameshift
rs199916659 is not expected to alter protein function.
Overall, among 387 ISGs examined in 7595 individuals, more
than half of the genes carried a stop-gain or frameshift variant in 1
or more individuals, usually at low allele frequency. Of these, 12
individuals carried truncating variants consistently interpreted as
highly pathogenic by the three evaluated scores. This rate of 1.5
per 1000 carriers could be a genomic substrate of occasional
homozygosity with unknown phenotypic consequences.
We then evaluated those instances that concerned genes for
which an antiviral effect has been established through a gain-of-
function screen in vitro. This last analysis provided a short list of
genes and reliable variants that could modulate responses to
various viruses, including common human pathogens such as
influenza. Of note, the in vitro virological inhibition data
represents a technical readout, and there are a number of
considerations that may diminish the in vivo consequences of these
rare variants, including issues of redundancy and robustness
in innate immunity networks, and the possibility of stop codon
Figure 6. Discrimination of pathogenic and non-pathogenic variants within OMIM genes according to the degree of gene
conservation. Shown are boxplots representing the distribution of the average sequence-based score of pathogenic (dark grey) and non-
pathogenic/non-annotated (orange) stop-gain variants in OMIM genes depicted in Figure 5. The distributions of the corresponding MacArthur 2012
and RVIS gene-based scores are shown in light grey. Genes are represented in two categories according to their conservation level in primates: dN/dS
ratio below (Panel A; n = 54) and above (Panel B; n = 20) the protein-coding genome average.
doi:10.1371/journal.pcbi.1003757.g006
Figure 7. Pathogenicity score distributions for rare stop-gain variants in innate immunity genes. Rank percentile distributions of
pathogenicity scores for rare stop-gain variants (MAF,1%) are shown in different sets of genes: protein coding genome background (grey,
‘‘Genome’’), innate immunity genes (light turquoise, ‘‘Inn Imm’’) and their subset of interferon stimulated genes (dark turquoise, ‘‘ISGs’’). The same
categories are shown for OMIM disease variants. All variants are reported in ESP and 1000 Genomes datasets except for sets indicated with the 1
symbol (dashed boxes) which present scores for OMIM disease variants only reported in the OMIM database. Only three variants reported in ESP and
1000 Genomes were found to affect ISGs and annotated as pathogenic in OMIM; this category is not represented in the figure. Variants with the
highest probability of being pathogenic have rank percentiles closer to zero (top of the panels). Panel A represents precomputed gene-based
pathogenicity scores from [19]. Panel B represents sequence-based pathogenicity scores, i.e. posterior probabilities using the features described in
the present work (see main text). Distributions of rank percentiles are represented as boxes where each box spans between 1st and 3rd quantile, and
the median is denoted by a bold line in the middle. Total number of variants within each distribution is indicated. Differences in number of variants in
equivalent categories between panel A and B originate from unavailability of the gene-based scores for some genes. Statistical differences against
the genome reference (one-sided Wilcoxon rank sum tests) are indicated with asterisks according to Bonferroni corrected p-values: ,5e-02 (*), ,5e-
03 (**) and ,5e-04 (***). The genome-wide median is denoted by a red line. Spearman correlation between the sequenced-based and gene-based
pathogenicity scores was below 0.31 in all sets of genes analyzed (Figure S5).
doi:10.1371/journal.pcbi.1003757.g007
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read-through. There are other limitations to the predictions based
on sequence features, particularly the incomplete understanding of
the functional role of alternative isoforms and their tissue
specificity.
Rare gene truncating variants predicted to have high pathoge-
nicity risk in innate immunity genes should be examined for
phenotypic consequences in the population. Exceptional homozy-
gous individuals may be at risk for severe infection while
heterozygous individuals could have adequate compensation or
subtler phenotypes. However, there is increasing awareness of the
relevance of haploinsufficiency [31], and thus, it is not excluded
that heterozygosity may be associated with apparent clinical
phenotypes. Thus, the next step should include assessment in vivo
of high risk variants, which requires the capacity to re-contact




Two genetic variant and annotation datasets were used: 1) 6503
individuals from the NHLBI GO Exome Sequencing Project
(ESP) [16] and 2) 1092 individuals from the 1000 Genomes
Project [21]. Variants (SNPs and INDELs) and annotations for the
ESP exomes (file ESP6500SI-V2-SSA137.dbSNP138-rsIDs.snp-
s_indels.txt.tar.gz) were downloaded from the Exome Variant
Server, NHLBI GO Exome Sequencing Project, Seattle, WA
(http://evs.gs.washington.edu/EVS/, accessed July 2013). Only
variants assigned to the following categories were considered for
further analysis: ‘‘stop-gained’’ (including ‘‘stop-gained-near-
splice’’), ‘‘frameshift’’, ‘‘coding-synonymous’’ (including ‘‘coding-
synonymous-near-splice’’) and ‘‘missense’’ (including ‘‘missense-
near-splice’’). One base was added to the genomic coordinates
reported for frameshifts in the ESP dataset to consider the actual
location of the insertion/deletion event (http://evs.gs.washington.
edu/EVS/HelpDescriptions.jsp?tab = tabs-1). Variants and geno-
types from the 1000 Genome Project [21] correspond to phase 1
version 3 of the 20110521 release (ftp://ftp.1000genomes.ebi.ac.
uk/vol1/ftp/release/20110521/, accessed August 2013). SnpEff
Variant Analysis software [32] (version 3.3h build 2013-08-11) was
used to annotated 1000Genome variants against SnpEff’s pre-built
human database (GRCh37.71). SnpEff categories labeled with
errors or warnings in the EFF field were disregarded. Only
variants assigned to the following categories were considered for
further analysis: ‘‘stop_gained’’, ‘‘frame_shift’’, ‘‘synonymous_cod-
ing’’ (including ‘‘synonymous_start’’ and ‘‘synonymous_stop’’) and
‘‘non_synonymous_coding’’ (missense). Hardy-Weinberg equilib-
rium (HWE) was tested with R package GWASExactHW (http://
cran.r-project.org/web/packages/GWASExactHW/, version
1.1). A fraction of variants significantly deviated from HWE
(Fisher’s exact p-values,0.05), mainly due to an excess of
homozygous rare allele calls, likely indicating technical artifacts.
All variants not in HWE were filtered out. When both datasets
where considered together, the following criteria were adopted: i)
Genomic coordinates of frameshift variants reported by both
datasets were treated as reported for the ESP dataset. ii) Allele
frequencies and HWE of variants present in both datasets were
derived from the sum of individuals from both studies; allele
frequencies of variants present in only one dataset were taken as
originally reported by the corresponding dataset. To exclude bias
due to previous assumptions, results were reproduced for the two
datasets considered separately as well as combined. For the
combined analysis allele frequencies of variants present in only one
dataset are estimated over all 7593 individuals.
Annotation of variants in reference human transcript and
protein sequences
The analysis pipeline implemented to annotate genetic variants
is depicted in Figure S7. We restricted the analysis to protein
coding genes and transcripts annotated by the Consensus CDS
(CCDS) project [23] (ftp.ncbi.nlm.nih.gov/pub/CCDS/, Release
12 04/30/2013). We considered only variants affecting a core set
of human protein coding regions consistently annotated and of
high quality. Only genes on the 22 autosomes were retained and
only CCDS entries with a public status and an identical match
were kept.
Domains of human protein sequences were retrieved from the
InterPro database [33] (release 44.0, 23/09/2013). Data were
downloaded through BioMart Central Portal [34] (http://central.
biomart.org/, accessed 04/10/2013), filtering fragments and
considered domain boundaries corresponding to InterPro ‘‘super-
matches’’. Mapping from InterPro coordinates on UniProt protein
sequences to CCDS sequences was done by exact matching of the
complete amino acid sequences using UniProt database (release
2013_07; [35]).
A position within a protein coding gene was considered
alternatively spliced if it was shared by only a fraction of all
protein coding transcripts reported by the Consensus CCDS
Project for that gene. Otherwise it was considered constitutively
spliced for the purpose of the study. Annotation of principal
isoforms used APPRIS ([36]; file APPRIS-g15.v3.15Jul2013/
appris_data.principal.homo_sapiens.tsv accessed 03/09/2013 at
URL: http://appris.bioinfo.cnio.es), a computational pipeline and
database for annotations of human splice isoforms. APPRIS selects
a specific transcript as principal isoform, i.e. the one computa-
tionally predicted as responsible of the main cellular function,
being expressed in most of the tissues or developmental stages and
more evolutionary conserved. Selection of the principal isoform is
based on protein structure, function and interspecies conservation
of transcripts. As an alternative definition of principal isoform, we
identified the transcript with a recurrent highest expression level
across tissues as provided by [25].
We accounted for nonsense-mediated decay (NMD) following
HAVANA annotation guidelines v.20 (05/04/2012) (http://
www.sanger.ac.uk/research/projects/vertebrategenome/havana/
assets/guidelines.pdf), Specifically, the NMD-target region of a
transcript was defined as those positions more than 50 nucleotides
upstream the 39-most exon-exon junction. Transcripts bearing
stop-gain variants at these regions are predicted to be degraded by
NMD [13].
Functional validation using mRNA expression data
Geuvadis RNA sequencing data from 421 lymphoblastoid cell
lines from the 1000 Genomes Project (phase 1 version 3 of the
20110521 release, see above; [21]) were obtained from Lappalai-
nen et al. 2013 [22]. Gene expression quantifications of protein-
coding genes were downloaded from EBI ArrayExpress accession
E-GEUV-1 (accessed 05/11/2013). Analyses were independently
performed on both RPKM and Peer-factor normalized RPKM
values. As a measure of the impact of a variant on expression level,
we calculated the average Z-score of the expression level in cells
from individuals carrying the variant compared to all samples.
Derivation of sequence-based pathogenicity score
We used a naı¨ve Bayes classification scheme in order to derive a
probability of pathogenicity for a given variant using the following
sequence-based features: maximum transcript length affected,
maximum percentage of domain truncation, number of isoforms
Stop-Gains and Frameshifts in Human Innate Immunity Genes
PLOS Computational Biology | www.ploscompbiol.org 8 July 2014 | Volume 10 | Issue 7 | e1003757
and ratio of isoforms affected, truncation of the principal isoform
and localization in an NMD-target region. Solely for the purpose
of the classifier, missing values were imputed to zero for
percentage of domain truncation and to the longest isoform for
principal isoform annotation. We defined a matrix XN6K of K
sequence-based features for N variants of a given type in the
dataset and a binary vector cN61 annotating variants as benign or
pathogenic. A new variant, y16K, is evaluated using maximum
likelihood estimates for class-specific means from the annotated
data, and a common intra-class variance vector (except for binary
features). We estimate the variance vector as n=E[(xi - mci)
2],
where xi is the i
th row in matrix X and mci is the mean vector
corresponding to the class indicated by ci,. We assigned a
pathogenic class with 1 and benign class with 0. Assuming a prior
probability of pathogenicity, p1, posterior probability of pathoge-













where p0 = 1-p1 is the prior probability of being benign and
h={m1,m2,n} is the set of model parameter vectors. The
conditional likelihood of y for a given class is assumed to factorize
as product of K likelihoods corresponding to the K sequence
features available (naı¨ve Bayes assumption). We used normal, and
Bernoulli likelihood functions to model continuous and binary
features respectively. It is straightforward to show the ranking
produced from this posterior probability does not depend on the
prior probability p1 as long as it is larger than zero and it is equal
for all the mutations under consideration.
Evaluation of pathogenicity scores
As reference throughout the work, and as a learning set for the
predictive scores (ROC analyses), we used a catalogue of
pathogenic mutations from the Online Mendelian Inheritance in
Man [37] database. Only genes with a cytogenetic location
(genemap2.txt accessed 18/10/2013 at OMIM: ftp.omim.org) and
with a gene status of confirmed or provisional were kept. For each
gene with an associated OMIM number, all allelic variants with a
‘‘live’’ status and a dbSNP identifier were obtained through the
OMIM API server (http://api.omim.org/). We used Ensembl
Variation [38] (Ensembl release 71, April 2013, dataset Homo
sapiens Short Variation, SNPs and indels, GRCh37.p10, accessed
25/10/2013 at http://apr2013.archive.ensembl.org/biomart/
martview/) to obtain the genomic coordinates for each dbSNP
identifier together with the clinical significance of each specific
allele as reported by ClinVar and dbSNP following OMIM
guidelines (http://www.ncbi.nlm.nih.gov/clinvar/docs/clinsig/).
Only variants with a dbSNP identifier annotatted as ‘‘pathogenic’’
and mapping to a unique genomic location were kept for further
analysis. SnpEff Variant Analysis was then used to re-annotate the
selected pathogenic variants as described above.
We benchmarked three different pathogenicity scores using all
stop-gain variants from the OMIM dataset as positive (pathogen-
ic), and all common variants (MAF$1%) not present in OMIM
dataset as negative (benign) variants. The sequence-based score is
the posterior probability calculated from the naı¨ve Bayes
classification scheme described in previous section using an
empirical prior for pathogenicity. We used two different gene-
based scores: first the probability provided by MacArthur et al [19]
for prioritization of variants derived from two gene-level features:
conservation and protein interaction network proximity to genes
associated with a recessive disease. And second the Residual
Variation Intolerance Score (RVIS) [6] that provides a measure of
the departure from the average number of common functional
mutations in genes with a similar amount of mutational burden.
RVIS pathogenic score was assessed as f(-RVIS), where f(.) is the
logistic function. The joint score was defined as the product of the
sequence-based score and one of the two previously defined gene-
based scores. This joint score can be interpreted as the joint
probability of a pathogenic mutation in a gene assuming
conditional independence of the two probability scores. The
receiver operating characteristic (ROC) curve was derived using
random subsampling validation iterations. In each iteration, we
use 75% of the data to train the classifier and use the remaining
25% for validation. This was done 10000 times, to minimize the
Monte Carlo error, and validation set scores were combined to
calculate the ROC curve. The same procedure was applied to
frameshift variants.
Except for ROC analyses, sequence-based scores used through-
out the work were derived from the learning set described above
excluding both i) OMIM pathogenic variants reported in ESP and
1000 Genomes Project and ii) OMIM pathogenic variants
affecting innate immunity genes and interferon stimulated genes.
Assessment of dN/dS values
Genome-wide codon alignments of orthologous genes for nine
primate species (human, chimpanzee, gorilla, orangutan, ma-
caque, marmoset, tarsier, bushbaby, and mouse lemur) were
collected from Ensembl v57. We assessed dN/dS estimates using
both Ensembl Compara’s protein-based alignments, and DNA-
based alignments of primate sequences generated from genomic
DNA alignments. Sitewise Likelihood Ratio test [39] was used to
calculate the overall dN/dS for a given gene based on a one-ratio
model where all sites have the same dN/dS value.
Analysis of innate immunity genes and interferon
stimulated genes (ISGs) with antiviral activity
A representative list of 1503 human innate immunity genes [20]
was used. Within this list, we further analyzed 387 interferon
stimulated genes (ISGs) [26]. Additionally, we focused on those
ISGs showing antiviral activity against 18 viruses (including
important human pathogens such as HIV-1, hepatitis C virus,
influenza virus and other respiratory viruses) upon overexpression
in in vitro cellular assays [26,27]. We first identified all ISGs
carrying gene truncating variants, and then characterized the
subset of those genes associated with more than 50% viral
inhibition in the cellular assays.
Supporting Information
Figure S1 Distribution of variants along the gene
sequence. The distribution is shown for synonymous (green),
missense (blue), stop-gain (red) and frameshift (orange) variants
binned by minor allele frequency (MAF) intervals: Singletons (panel
A), MAF,0.001 (Panel B), MAF5 [0.001–0.01) (Panel C), MAF
5 [0.01–0.05) (Panel D) and MAF.0.05 (Panel E). Numbers of
variants in each category are reported in Table S1. Data were
combined across the sequence using intervals of 10%. The longest
transcript for each gene was used as the reference sequence length.
(TIF)
Figure S2 Distribution of variants according to se-
quence features and allele frequency represented sepa-
rately for the ESP and the 1000 Genomes datasets. The
percentage of variants upstream of a functional domain (Panels A
and E), in alternatively spliced sites (Panel B and F), in the
Stop-Gains and Frameshifts in Human Innate Immunity Genes
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principal isoform (panel C and G) and in regions targeted by
NMD (Panel D and H). Panels A, B, C and D correspond to
variants in the ESP dataset, and panels E, F, G and H to the 1000
Genomes dataset. The distribution is shown for synonymous
(green), missense (blue), stop-gains (red) and frameshift (orange)
variants according to minor allele frequency (MAF) intervals,
where singletons (variants detected only in one individual) are
represented separately. The pattern of OMIM disease variants and
homozygous variants for each feature is shown. The correspond-
ing coding genome background (measured as the percentage of
nucleotides displaying the feature) is shown as a grey line (partly
hidden by the distribution of synonymous variants in some panels).
The y-axis represents the percentage of variants for the categories
represented in the x-axis. Logistic regression was used to model the
relationship between observing a given sequence feature in a given
type of variant as a function of the logarithm of the minor allele
frequency (MAF). In the ESP dataset, the odds ratio estimates for
stop-gain variants were significantly different from those of
synonymous variants in all panels (p-values,1e-04, heterogeneity
test [1]; for frameshifts, in panels B, C and D (p-values,5e-02). In
the 1000G dataset, the odds ratio estimates for stop-gain variants
were significantly different from those of synonymous variants in
all panels (p-values%5e-02, heterogeneity test [1]; for frameshifts,
in panel F (p-value,5e-02). Distribution for frameshift variants
from the 1000 Genomes dataset is noisy due to small sample size
(Table S1).
(TIF)
Figure S3 Association of NMD-target variants with gene
expression using standard RPKM normalization. Results
in Figure 2 are reproduced here using standard RPKM
normalized expression values from Lappalainen et al. [2]. Panel
A shows the distribution of average expression z-scores for genes
from individuals carrying different types of variants (synonymous,
missense, frameshift and stop-gain). The black half represents the
distribution of variants outside the NMD-target region and the
colored half for those within the NMD-target region. As in
Figure 2, statistically significant differences were observed for
stop-gain variants predicted to trigger NMD (n = 756) compared
to synonymous variants (one-sided Wilcoxon rank-sum test p-
value,2.2e-16). Panel B shows the distribution of average
expression z-scores described in panel A for synonymous (grey)
and stop-gain (dark and light purple) variants within the NMD-
target region. The distribution of NMD-target stop-gains is
represented separately for singletons (dark purple, n = 488) and
non-singletons (n = 268). Distributions are statistically different
(one-sided Wilcoxon rank-sum test = 4.4e-10). Panel C shows the
distribution of average expression z-scores described in panel A for
synonymous (grey) and stop-gain (dark and light pink) variants
within the NMD-target region of genes with multiple isoforms
described in CCDS. The distribution of NMD-target stop-gain is
represented separately for those affecting all isoforms (dark pink,
n = 216) and those affecting only a fraction of isoforms (light pink,
n = 85). As in Figure 2, distributions are statistically different
(one-sided Wilcoxon rank-sum test = 1.5e-03).
(TIF)
Figure S4 Receiver operating characteristic of the
performance of pathogenicity scores for stop and
frameshift variants. Shown are the ROC curves correspond-
ing to the sequence-based classifier (SB) developed in this work, a
gene-based scores (GB) (Panels A–F: MacArthur 2012 [3];
Panels G–L: RVIS [4]), and the joint score combining the
sequence-based and a gene-based score (SB6GB). Dashed curves
correspond to a randomization test in which rows in sequence
features are shuffled column-wise (denoted by SB(r) and GBxSB(r)).
Classification power was evaluated on a set of pathogenic variants
found in OMIM database (referred in the figure as Positives (Pos),
and common variants not known to be pathogenic (referred in the
figure as Negatives (Neg). Total number of Positive and Negative
variants used is indicated above each panel. Panels A–C and G–I
represent stop-gain variants while Panels D–F and J–L represent
frameshif variants. Results are shown for both the ESP and 1000
Genomes datasets considered together (Panels A, D, G, J) or
separately (Panels B, E, H, K for the ESP dataset and panels
C, F, I, L for the 1000 Genomes dataset). Number of pathogenic
and common variants used for benchmarking is shown on top of
each panel. AUC values of ROC curves for each model are
indicated. Incorporating sequence features led to an increased area
under the ROC curve in all evaluated settings (Figure 3B).
(TIF)
Figure S5 Correlation between sequence-based scores
and gene-based scores for truncating variants. Figure
shows the correlation between the sequence-based pathogenicity
score developed in this work and two gene-based pathogenicity
scores (Panels A and D: MacArthur 2012 [3]; Panels B and E:
RVIS [4]). Correlation between the two gene-based scores is
shown in Panels C and F. Panels A–C represent values for
17645 stop-gain variants reported by the ESP and the 1000
Genomes datasets (panels A–C). Panels D–F represent values for
155 disease stop-gain variants annotated as pathogenic by OMIM
and reported by the ESP and the 1000 Genomes datasets (we note
that OMIM variants used here were not considered for learning in
the Bayesian classification; see Methods). Upper Panels A–C
display the distribution of the score on the y-axis in the form of
boxplots conditioned to decile bins of the score on the x-axis.
Lower Panels D–E represent the values for each individual
OMIM variant (depicted with cross marks). For comparison across
scores, they are represented as rank percentiles, where the value of
a given variant accounts for the percentage of all stop-variants that
had a score more pathogenic than the variant. Therefore, a rank
percentile of ‘‘0’’ indicates a variant with the highest predicted
probability of being pathogenic while a rank percentile of ‘‘100’’
indicates a variant with the lowest predicted severity. Grey
triangles beside the panels represent the direction of increasing
pathogenicity for the corresponding variable. Lines in Panels D–
F divide variants in four regimes according to their belonging to
the top 20% pathogenicity ranking of the corresponding scores,
the top-right regime being the one where both scores agreed.
Spearman rank correlation tests yielded significant p-values in
panels A–C (p-value,2.2e-16). Spearman correlations were ,
0.13 (panels A and B; [0.107,0.125] and [0.115,0.123] 95% CI
from 10,000 bootstrap samples, respectively), ,0.24 (panel C;
[0.224,0.241] 95% CI). No significant p-values were found in
panels D–E (Spearman correlation ,0.07). Similar figures were
obtained for frameshift variants in analogous analyses to panels A–
C. Analogous analyses to panels D–E on frameshifts variants were
not possible due to lack of OMIM pathogenic frameshift variants
in the ESP and 1000 Genomes datasets.
(TIF)
Figure S6 Pathogenicity score distributions for rare
frameshift variants in innate immunity genes. Rank
percentile distributions of pathogenicity scores for rare frameshift
variants (MAF,1%) are shown in different sets of genes: protein
coding genome background (grey, ‘‘Genome’’), innate immunity
genes (light turquoise, ‘‘Inn Imm’’) and their subset of interferon
stimulated genes (dark turquoise, ‘‘ISGs’’). In contrast with
Figure 7, the same categories for OMIM disease frameshifts
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are not shown due to low number or absence of variants. All
variants are reported in ESP and 1000 Genomes Projects.
Variants with the highest probability of being pathogenic have
rank percentiles closer to zero (top of the panels). Panel A
represents precomputed gene-based pathogenicity scores from [3].
Panel B represents sequence-based pathogenicity scores, i.e.
posterior probabilities using the features described in the present
work (see main text). Each box spans between 1st and 3rd quantile,
and the median is denoted by a bold line in the middle. Total
number of variants within each distribution is indicated.
Differences in number of variants in equivalent categories between
panel A and B originate from unavailability of the gene-based
scores for some genes. Statistical differences against the genome
reference (one-sided Wilcoxon rank sum tests) are indicated with
asterisks according to Bonferroni corrected p-values:,5e-02 (*),,
5e-03 (**) and ,5e-04 (**). The genome-wide median is denoted
by a red line. Spearman correlation between the sequenced-based
and gene-based pathogenicity scores was below 0.13 in all sets of
genes analyzed.
(TIF)
Figure S7 Pipeline implemented to annotate genetic
variants in reference human transcripts and protein
sequences. Figure depicts the schematic pipeline followed for the
annotation of variants (see Methods). Analysis was restricted to
variants affecting autosomal protein coding genes and transcripts
annotated by the Consensus CDS (CCDS) project ([5]. Annotation
of principal isoforms used APPRIS system ([6]. Transcript-based
information was related to protein-based information through
UniProt [7]. InterPro database ([8] was used to retrieve protein
domain information.
(TIF)
Table S1 Distribution of variants according to allele
frequency and dataset. Number of variants included in the
study is reported in total and according to their original dataset:
the NHLBI GO Exome Sequencing Project (ESP) and the 1000
Genomes Project. Distribution is shown according to variant type
and minor allele frequency intervals and the number of genes
bearing each type of variants is reported.
(XLSX)
Table S2 Distribution of variants displaying different
sequence features according to allele frequency. Table
shows the absolute numbers and corresponding percentages of the
distributions of variants shown in Figure 1. Absolute number (1),
reference number (2) and percentage (3) of variants upstream of a
functional domain (A), in alternatively spliced sites (B), in the
principal isoform (C) and in regions targeted by NMD (D) are
shown according to minor allele frequency intervals. Correspond-
ing figures are reported for OMIM disease variants and
homozygous variants together with a coding genome background
reference measured in nucleotides.
(XLSX)
Table S3 Parameters of the Naı¨ve Bayesian classifier
learned from the joint dataset.
(XLSX)
Table S4 Sequence features and pathogenicity scores of
gene truncating variants in antiviral interferon stimu-
lated genes. Table shows figures for 15 stop-gain and 7
frameshift variants affecting 13 of 42 genes with anti-viral activity
in cellular assays [9] [10]. Analysis was restricted to variants
identified in at least two individuals. Variants are ranked
according to their sequence-based pathogenicity score. High-
scoring variants affecting MX1 and HPSE are highlighted in
violet and green respectively and discussed in the main text.
(XLSX)
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